



## High-throughput epitope profiling of snake venom toxins unveiling the complexity of antigen-antibody interactions of antivenoms

Engmark, Mikael; Andersen, Mikael Rørdam; Laustsen, Andreas Hougaard; Patel, Jigar; Sullivan, Eric; De Masi, Federico; Hansen, Christian Skjødt; Kringelum, Jens Vindahl; Lomonte, Bruno; Gutiérrez, José María

Total number of authors:  
11

Publication date:  
2016

Document Version  
Publisher's PDF, also known as Version of record

[Link back to DTU Orbit](#)

### Citation (APA):

Engmark, M., Andersen, M. R., Laustsen, A. H., Patel, J., Sullivan, E., De Masi, F., Hansen, C. S., Kringelum, J. V., Lomonte, B., Gutiérrez, J. M., & Lund, O. (2016). *High-throughput epitope profiling of snake venom toxins: unveiling the complexity of antigen-antibody interactions of antivenoms*. Poster session presented at The 12th Congress of the Pan-American Section of the International Society on Toxinology, Miami Beach, Florida, United States.

---

### General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.



# High-throughput epitope profiling of snake venom toxins

## – unveiling the complexity of antigen-antibody interactions of antivenoms


Mikael Engmark<sup>1,2</sup>, Mikael R. Andersen<sup>2</sup>, Andreas H. Laustsen<sup>2,3</sup>, Jigar Patel<sup>4</sup>, Eric Sullivan<sup>4</sup>, Federico de Masi<sup>1</sup>,

Christian S. Hansen<sup>1</sup>, Jens V. Kringelum<sup>1</sup>, Bruno Lomonte<sup>5</sup>, José María Gutiérrez<sup>5</sup>, and Ole Lund<sup>1</sup>

### Introduction

Insight into the molecular details of polyclonal antivenom antibody specificity is a prerequisite for accurate prediction of cross-reactivity and can provide a basis for design of novel antivenoms<sup>1</sup>. In this work, a high-throughput approach was applied to characterize linear elements in epitopes in 82 toxins from four African mamba and three neurotoxic cobra snakes obtained from public databases.

### Studying linear epitopes using peptide microarrays



### High number of epitopes recognized by SAIMR antivenom




Figure 1. (A-C) Venn diagrams of peptides classified to bind antivenom antibodies for each pair of experiments conducted with the same antivenom in two different dilutions; (A) SAIMR Polyvalent Snake Antivenom, (B) VINS African, and (C) VINS Central Africa. (D) Venn diagram of peptides classified as binders for each antivenom. Only peptides identified in both experiments with each antivenom, corresponding to the overlap in Venn diagram in part A-C, are included.

### Key residues for antivenom toxin recognition




Figure 2. Examples of B-cell epitope analysis: Type 1 and 2  $\alpha$ -neurotoxin and dendrotoxins recognized by the SAIMR polyvalent antivenom. The filled profiles above each sequence represent the average score of peptides containing a given peptide. The tile background represents the average alanine substitution effect. When no 12-mer peptide covering a given residue passed the epitope-threshold, the residue is colored gray. Dark purple indicates that a residue is of particular importance for antibody recognition.

### Antivenoms antibodies bind to functional sites of toxins




Figure 3. Structural presentation of B-cell epitope analysis: (A-B) Short neurotoxin 1 (P01416) from *D. polylepis* as an example of a type 1  $\alpha$ -neurotoxin. Structure built upon<sup>1</sup>; (C-D) Fasciculin-2 (P0C1Z0) from *D. angusticeps* as an example of a fasciculin. The Fasciculin-2 is co-crystallized with the human acetylcholinesterase enzyme. Structure built upon<sup>2</sup>; (E-F) Toxin FS-2 (P01414) from *D. polylepis* as an example of an L-type calcium channel blocker. Structure built upon<sup>3</sup>; (G-H)  $\alpha$ -elapitoxin-Dpp2c (P01397) from *D. polylepis* as an example of a type 2  $\alpha$ -neurotoxin. Structure built upon<sup>4</sup>. (A,C,E,G) Residues colored according to alanine substitution effect in log2 fold-change, where magenta indicates that a residue is of particular importance for antibody recognition. Residue numbers refer to original sequence and not alignment; (B,D,F,H) Residues colored according to residue score, where dark red refers to residues with high residue score, and blue refers to residues with low residue scores.

### Conclusions

Custom-designed high density peptide microarray technology enables parallel automated identification of linear elements of epitopes in snake neurotoxins.

Trend: antivenom antibodies recognize and bind to epitopes at the functional sites of toxins.

### Perspectives

Determination of linear elements in snake venom toxin epitopes may provide the basis for:

- Explaining the molecular basis of antivenoms para-specificity
- Guiding next-generation antivenoms based on DNA immunization and immunization with synthetic epitope strings<sup>5</sup>

### Affiliations

- Technical University of Denmark, Department of Bio and Health Informatics, Kgs. Lyngby
- Technical University of Denmark, Department of Biotechnology and Biomedicine, Kgs. Lyngby
- University of Copenhagen, Department of Drug Design and Pharmacology, Faculty of Health and Medical Sciences, Denmark
- Roche NimbleGen, Madison, Wisconsin, USA
- Instituto Clodomiro Picado, Facultad de Microbiología, Universidad de Costa Rica, San José

### References

- Labhardt, A. M. et al. *European Journal of Biochemistry* 177, 295–305 (1988)
- Cheung, J. et al. *Journal of Medicinal Chemistry* 55, 10282–10286 (2012)
- Albrand, J. et al. *Biochemistry* 34, 5923–5937 (1995)
- Wang, C. A. et al. *Biochemistry* 53, 3758–3766 (2014)
- Ramos, H. R. et al. *PLOS Neglected Tropical Diseases* 10, e0004484 (2016)

### Acknowledgement

We would like to thank Morten Nielsen for scientific discussion and the Novo Nordisk Foundation for financial support (grant number NNF13OC0005613)

